A Reversal for Medifast, Inc. (MED) Is Not Near. The Stock Reaches 52-Week High Today

May 16, 2018 - By Robert Sims

Medifast, Inc. (NYSE:MED) Logo

Investors sentiment increased to 1.33 in Q4 2017. Its up 0.33, from 1 in 2017Q3. It is positive, as 14 investors sold Medifast, Inc. shares while 56 reduced holdings. 36 funds opened positions while 57 raised stakes. 10.23 million shares or 0.32% more from 10.20 million shares in 2017Q3 were reported.
Aperio Gru Lc reported 0.02% of its portfolio in Medifast, Inc. (NYSE:MED). Fny Managed Accounts Ltd Liability Corp stated it has 0% of its portfolio in Medifast, Inc. (NYSE:MED). Morgan Stanley reported 76,652 shares stake. Panagora Asset accumulated 1,131 shares. Hightower Advsrs Limited Liability Corp holds 7,096 shares or 0% of its portfolio. First Citizens State Bank And Communications holds 0.03% in Medifast, Inc. (NYSE:MED) or 3,393 shares. Moreover, Credit Suisse Ag has 0% invested in Medifast, Inc. (NYSE:MED). Laurion Capital L P holds 0.03% of its portfolio in Medifast, Inc. (NYSE:MED) for 77,177 shares. Quantbot Lp holds 1,023 shares. Victory Cap Mgmt reported 0% stake. Brown Brothers Harriman And Communications invested 0% of its portfolio in Medifast, Inc. (NYSE:MED). Geode Mngmt Lc accumulated 0% or 187,558 shares. Stifel stated it has 0% in Medifast, Inc. (NYSE:MED). Moreover, Rhumbline Advisers has 0% invested in Medifast, Inc. (NYSE:MED). Rice Hall James And Assoc Ltd Com has 38,770 shares.

Since March 8, 2018, it had 0 buys, and 3 sales for $4.87 million activity. MACDONALD MICHAEL C also sold $3.47 million worth of Medifast, Inc. (NYSE:MED) on Thursday, March 8.

The stock of Medifast, Inc. (NYSE:MED) hit a new 52-week high and has $138.46 target or 7.00 % above today’s $129.40 share price. The 8 months bullish chart indicates low risk for the $1.56 billion company. The 1-year high was reported on May, 16 by Barchart.com. If the $138.46 price target is reached, the company will be worth $109.27 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.50% or $0.65 during the last trading session, reaching $129.4. About 59,003 shares traded. Medifast, Inc. (NYSE:MED) has risen 107.05% since May 16, 2017 and is uptrending. It has outperformed by 95.50% the S&P500.

Analysts await Medifast, Inc. (NYSE:MED) to report earnings on August, 14. They expect $1.00 EPS, up 58.73 % or $0.37 from last year’s $0.63 per share. MED’s profit will be $12.06 million for 32.35 P/E if the $1.00 EPS becomes a reality. After $1.01 actual EPS reported by Medifast, Inc. for the previous quarter, Wall Street now forecasts -0.99 % negative EPS growth.

Another recent and important Medifast, Inc. (NYSE:MED) news was published by Seekingalpha.com which published an article titled: “Medifast’s (MED) CEO Dan Chard on Q1 2018 Results – Earnings Call Transcript” on May 04, 2018.

Medifast, Inc., through its subsidiaries, produces, distributes, and sells weight loss, weight management, healthy living products, and other consumable health and diet products. The company has market cap of $1.56 billion. The firm offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, eggs, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by Take Shape For Life, Flavors of Home, and Essential 1 brands, as well as Dual Fuel, a sports nutrition pilot program. It has a 56.51 P/E ratio. It also provides meal replacements comprising vitamins and minerals; and hydration products, as well as other nutrients for health purposes.

Medifast, Inc. (NYSE:MED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: